ClinicalTrials.gg
RecruitingNCT06844981Updated Nov 12, 2026

Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors

An interventional study of Latin Dance in Cancer Survivorship and Sleep Disturbances, sponsored by Rutgers, The State University of New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective is to assess the feasibility, acceptability and explore the impact of a culturally appropriate Latin Dance intervention vs. Usual Care on sleep quality for Hispanic cancer survivors.

Secondary objectives are to examine the preliminary efficacy of a culturally appropriate Latin Dance intervention on secondary cancer- and treatment-related side effects (e.g., Quality of Life, distress, insomnia, fatigue).

Read the detailed description

In this feasibility Randomized Control Trial (RCT) study, the investigators will assess the feasibility, acceptability, and explore the impact of a Latin dance intervention vs usual care on sleep quality among Hispanic survivors.

Study Aims:

Aim 1: Develop a culturally appropriate Latin dance intervention for Hispanic cancer survivors using a bidirectional community engagement approach. Using iterative qualitative feedback from Hispanic cancer survivors, the investigators will develop a Latin dance intervention for Hispanic cancer survivors.

Aim 2: Assess the feasibility and acceptability of a culturally appropriate Latin Dance intervention for Hispanic cancer survivors.

Aim 3: Provide preliminary evidence of the efficacy potential of a culturally appropriate Latin Dance intervention vs. usual care on subjective and objective sleep quality for Hispanic survivors.

02

Conditions studied

  • Cancer Survivorship
  • Sleep Disturbances

Browse trials for

Keywords

  • Cancer
  • Cancer Survivorship
  • Sleep Disturbances
  • Hispanic Cancer Survivors
  • Latin Dancing
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Rutgers, The State University of New Jersey is the lead sponsor of 507 studies on the registry; 132 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 18 years of age or older
  • Self-identify as Hispanic and/or Latino(a)
  • Have a confirmed diagnosis of a solid tumor or hematologic
  • Must have completed primary cancer treatment 3+ months prior to enrollment (e.g., chemotherapy, surgery, and/or radiation therapy but may be on hormonal therapy and/or immunotherapy or other long-term therapies)
  • Have sleep disturbance (indicated by a response of 3 or more on the MD Anderson Symptom Inventory sleep question by using an 11-point scale anchored by 0 [no sleep disturbance] and 10 [worst possible sleep disturbance]
  • Be able to read and understand English and/or Spanish
  • Physically Inactive (\<150 minutes of vigorous exercise/week within the past 3 months)

Exclusion criteria

Exclusion Criteria:

  • Current regular Latin dancing practice within the past year (2-3 times a week over a period of two months that is not interrupted).
  • Inability to speak and read English or Spanish proficiently
  • Inability to understand
  • Medical conditions that can cause sleep impairment: sleep apnea, restless leg syndrome, shift work
  • Regular use of a walker or wheelchair
  • Healing or unhealed fractures
  • Heart failure
  • \<12 months
  • Unwilling to be randomized to study arms and/or commit to 8 weeks of classes and a follow-up assessment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
50 participants (estimated)

Study arms

  • No intervention
    Usual care arm

    Participants in the usual care arm will receive care as usual and will not participate in the Latin Dancing program.

  • Experimental
    Intervention arm

    Participants in this arm will participate in the virtual Latin Dance group program that meets for 8 weeks, 2x each week, for 75 minute sessions.

    Behavioral: Latin Dance

Interventions

  • BehavioralLatin Dance

    Latin Dance intervention

    Also known as: intervention arm

06

What researchers measure

Primary outcomes

  1. Feasibility of the Intervention

    Feasibility in this study will include recruitment, adherence, and retention rates.

    Time frame: 8 weeks

  2. Treatment Perception Questionnaire (Acceptability of Intervention)

    Acceptability is defined as at least 80% of participants in the Latin Dance group agreeing or strongly agreeing that the intervention was acceptable via the Treatment Perceptions Questionnaire (TPQ). The TPQ consists of 10 statements about treatment satisfaction on a Likert-type scale from 0 (strongly disagree) to 4 (strongly agree). Average scores ≥ 3 indicated acceptable satisfaction.

    Time frame: Post-intervention (at approximately 8 weeks)

  3. Pittsburgh Sleep Quality Index

    Changes in sleep quality will be assessed pre and post-intervention with the Pittsburgh Sleep Quality Index (PSQI). The PSQI measures sleep quality with a total score ranging from 0-21 with higher scores indicating worse sleep quality.

    Time frame: Baseline and post-intervention (approximately 8 weeks)

Secondary outcomes

  1. Functional Outcomes for Cancer Therapy - General

    Quality of Life will be assessed via the Functional Outcomes for Cancer Therapy - General (FACT-G). This measure consists of 27 items designed to measure four domains of quality of life in cancer patients: physical, social, emotional, and functional well-being. Coefficients of reliability and validity are uniformly high. The physical, social, and functional domain scores range from 0-28 with higher scores indicating better quality of life. The emotional domain score ranges from 0 - 24 with higher scores indicating better quality of life. The FACT-G total score ranges from 0 - 108, with higher scores indicating better quality of life.

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  2. Functional Assessment of Chronic Illness - Fatigue

    Fatigue will be assessed with the Functional Assessment of Chronic Illness - Fatigue (FACIT-F) Scale. Higher scores indicate less fatigue (score range=0-52).

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  3. Patient Health Questionnaire - 2 (PHQ-2)

    The PHQ-2 is a two-item screening questionnaire for depression that asks about the frequency of a depressed mood and loss of interest or pleasure in the last two weeks. Each of the two questions is scored from 0 to 3, based on frequency. The two scores are added together for a total score ranging from 0 to 6. A total score of 3 or higher indicates a positive screen for depression.

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  4. Generalized Anxiety Disorder - 7 (GAD-7)

    The GAD-7 is used for screening and measuring the severity of generalized anxiety disorder (GAD). The total score indicates the severity of anxiety, from minimal (0-4) to severe (15 and above)

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  5. Insomnia Severity Index

    Insomnia will be assessed with the Insomnia Severity Index (ISI). A 5-point Likert scale of 7 questions is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28 with higher scores indicating higher severity of insomnia.

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  6. Objective Symptoms of Insomnia- Sleep Duration Via Actigraphy

    Actigraphy will measure the number of minutes of actual sleep.

    Time frame: 2 weeks (worn for 1 week at Baseline and 1 week at post-intervention)

  7. Objective Symptoms of Insomnia- Wake After Sleep Onset Via Actigraphy

    Actigraphy will measure total minutes of wake time after sleep onset.

    Time frame: 2 weeks (worn for 1 week at Baseline and 1 week at post-intervention)

  8. Objective Symptoms of Insomnia- Sleep Efficiency via Actigraphy

    Actigraphy will measure the percent of time actually slept compared to intended time sleeping.

    Time frame: 2 weeks (worn for 1 week at Baseline and 1 week at post-intervention)

  9. Objective Symptoms of Insomnia- Sleep Latency Via Actigraphy

    Actigraphy will measure the minutes it takes for the participant to fall asleep.

    Time frame: 2 weeks (worn for 1 week at Baseline and 1 week at post-intervention)

  10. Charleson Comorbidity Index

    The Charleson Comorbidity Index consists of 19 items, each with an assigned weight from 1 to 6 according to the relative risk of dying within a year. In general, the absence of comorbidity is considered: 0-1 points; low comorbidity: 2 points; and high comorbidity: ≥3 points.

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  11. Physical Activity Daily Diaries

    The physical activity daily diary is designed to gather information about participants' daily physical activity patterns.

    Time frame: Physical activity daily diaries will be completed beginning 1 week pre-intervention, completed throughout the 8-week intervention, and 1-week post-intervention.

  12. Sleep Daily Diaries

    The sleep diary is designed to gather information about participants' daily sleep patterns.

    Time frame: Sleep daily diaries will be completed beginning 1 week pre-intervention, completed throughout the 8-week intervention, and 1-week post-intervention.

  13. Self-Efficacy for Exercise (SEE) Scale

    The Self-Efficacy for Exercise (SEE) scale is a questionnaire designed to measure an individual's confidence in their ability to exercise regularly. Participants rate their confidence on a scale, often from 0 (not at all confident) to 10 (very confident).

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  14. Short Acculturation Scale for Hispanics (SASH)

    The Short Acculturation Scale for Hispanics is a 12-item questionnaire developed to measure the degree of acculturation experienced by Hispanics in the United States. Scores range from 1 to 5, where higher scores indicate a greater level of acculturation to mainstream U.S. culture.

    Time frame: Baseline

  15. Discrimination in Medical Settings Scale

    The Discrimination in Medical Settings (DMS) scale is a 7-item questionnaire that measures patient-reported experiences of mistreatment in healthcare settings. It uses a 5-point Likert scale for each item, asking patients how often they have experienced specific scenarios, such as being treated with less courtesy or feeling a doctor is not listening to them. Higher scores on the scale indicate more frequent experiences of discrimination, and it is used to study disparities in healthcare.

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  16. Brief Pain Inventory (BPI)

    The Brief Pain Inventory (BPI) is a 9-item self-report tool that measures pain severity and how pain interferes with daily activities on a 0-10 scale, with higher scores indicating greater pain. It shows excellent reliability, with Cronbach's alpha typically between 0.80 and 0.95.

    Time frame: Baseline and post-intervention (approximately 8 weeks)

  17. Leisure Time Exercise Questionnaire of Godin and Shephard

    The Leisure-Time Exercise Questionnaire (LTEQ) by Godin and Shephard is a brief self-report measure that asks about the frequency of mild, moderate, and strenuous exercise during a typical week. Responses are converted into a weekly leisure activity score by weighting each intensity level. The LTEQ demonstrates good reliability, with Cronbach's alpha values around 0.80 and strong test-retest stability.

    Time frame: Baseline and post-intervention (approximately 8 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 12 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Apr 2027 and completion Mar 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 25, 2025
StartActual
Apr 1, 2026
Primary completionEst.
Apr 2027was Dec 2026
CompletionEst.
May 2027was Mar 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Apr 2027
Nov 12, 2026
Study completion
Mar 2027→May 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Dec 2026→Apr 2027
    Study completion Mar 2027→May 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06844981
Responsible party
Evelyn Arana, DrPH (Assistant Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Feb 25, 2025
Start date
Apr 1, 2026
Primary completion
Apr 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Evelyn Arana, DrPH
Contact
earana@CINJ.Rutgers.edu
908-642-0861
Arlette Chavez, MD
Contact
ac2758@CINJ.Rutgers.edu
732-715-4923
Evelyn Arana, DrPH
principal investigator · Rutgers Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion